Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System (VIVA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04861805 |
|
Recruitment Status :
Recruiting
First Posted : April 27, 2021
Last Update Posted : November 1, 2023
|
Sponsor:
P+F Products + Features GmbH
Collaborator:
Meditrial USA Inc.
Information provided by (Responsible Party):
P+F Products + Features GmbH
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a prospective, single arm, multicenter study in an expanding cohort of 150 symptomatic patients with severe aortic stenosis who will be followed up for up to 5 years.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Symptomatic Aortic Stenosis | Device: Vienna Aortic Valve SE System | Not Applicable |
The purpose of this trial is to determine the safety and effectiveness of the Vienna Aortic Valve SE System, a new self-expanding transcatheter heart valve, in patients with symptomatic severe aortic stenosis (SSAS). This is a prospective, single arm, multicenter study in an expanding cohort of symptomatic patients with severe aortic stenosis following the FIH feasibility study. The clinical investigation comprises 11 visits (V1 to V11). After implantation of the IMD at visit 2, safety and effectiveness assessment of the device will be performed at 30 days (V4), 3 months (V5), 6 months (V6), 1 year (V7) and every year thereafter up to 5 years post-implantation (V8 to V11).
In summary, the clinical investigation for the individual patient will end after 5 years with a full clinical evaluation. The primary study endpoints for safety and effectiveness will be reached at 30-day follow-up timepoint.
The clinical trial is completed after all 150 patients (including 10 patients from FIH study), that are not prematurely withdrawn, have completed their 5-year follow-up visit involving all specified assessments.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 150 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | This is a prospective, single arm, multicenter pivotal study in an expanding cohort of symptomatic patients with severe aortic stenosis (following the initial FIH feasibility study). |
| Masking: | None (Open Label) |
| Primary Purpose: | Other |
| Official Title: | A Two -Stage First in Human (FIH) Feasibility / Pivotal Study of the Vienna Aortic Valve SE System |
| Actual Study Start Date : | July 3, 2023 |
| Estimated Primary Completion Date : | July 2025 |
| Estimated Study Completion Date : | October 2030 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Vienna Aortic Valve
transcatheter aortic valve implantation (TAVI)
|
Device: Vienna Aortic Valve SE System
Vienna Aortic Valve SE system for TAVI. |
Primary Outcome Measures :
- All Cause Mortality (30 days) [ Time Frame: up to 30 days ]All-cause mortality at 30 days from the index procedure.
Secondary Outcome Measures :
- All-cause, cardiovascular and non-cardiovascular mortality [ Time Frame: up to 5 years ]All-cause, cardiovascular and non-cardiovascular mortality at 30 days, 3 months, 6 months, 1 year and every year thereafter up to 5 years post-implantation.
- Periprocedural death [ Time Frame: 72 hours ]Incidence of peri-procedural death (to capture intra-procedural events that result in immediate or consequent death ≤72 h post-procedure)
- Incidence of TAVI-related complications [ Time Frame: periprocedural and during index hospitalization ]
Incidence of TAVI-related complications:
- Valve-related complication requiring repeat procedure
- Vascular complications resulting in interventions
- Ventricular septal perforation ≤7 days after IMD implantation
- Acute kidney injury-Stage 2 or 3 ≤7 days post IMD implantation
- Coronary artery obstruction requiring intervention
- Atrio-ventricular block requiring pacemaker implantation
- Mitral valve apparatus damage or dysfunction
- Evidence of a new pericardial effusion/ tamponade related to the TAVI procedure
- Prosthetic valve endocarditis
- Prosthetic valve thrombosis
- Prosthetic valve mispositioning
- Prosthetic valve embolization
- Valve-related dysfunction (mean aortic valve gradient ≥20 mmHg, EOA ≤0.9-1.1 cm2 and/or DVI peak velocity >0.35 m/s, AND/OR moderate or severe prosthetic valve regurgitation)
- Cerebrovascular event [ Time Frame: Up to 5 years ]
Cerebrovascular event (at 30 days, 3 months, 6 months, 1 year and every year thereafter up to 5 years post-implantation):
- Stroke, defined as an acute episode of focal or global neurological dysfunction caused by the brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction
- Transient ischemic attack (TIA), defined as a transient episode of focal neurological dysfunction caused by the brain, spinal cord, or retinal ischemia, without acute infarction. The difference between TIA and ischemic stroke is the presence of tissue damage on neuro-imaging studies or new sensory-motor deficit persisting >24 h. By definition, a TIA does not produce a lasting disability.
- Life-threatening bleeding [ Time Frame: Up to 1 year ]Life-threatening bleeding (at 30 days, 3 months, 6 months and 1 year post-implantation).
- Conduction disturbances requiring permanent pacemaker implantation [ Time Frame: Up to 5 years ]Conduction disturbances requiring permanent pacemaker implantation (at 30 days, 3 months, 6 months, 1 year and every year thereafter up to 5 years post-implantation)
- Rehospitalization [ Time Frame: Up to 5 years ]Re-hospitalization for valve-related complications or worsening congestive heart failure (at 30 days, 3 months, 6 months, 1 year and every year thereafter up to 5 years post-implantation)
- Device Success [ Time Frame: 72 hours ]
Device success defined as:
a. correct positioning of a single prosthetic investigational heart valve in the proper anatomical location AND ability to provide appropriate hemodynamic AND absence of peri-procedural mortality within 72 hours after implantation
- Technical success [ Time Frame: up to 30 days ]
Technical success defined as
- successful vascular access, delivery and deployment of the IMD and successful retrieval of the delivery system; and
- correct positioning of a single prosthetic investigational heart valve in the proper anatomical location
-
in patients alive at 30 days with implanted Vienna valve:
- Total aortic regurgitation of none/trace/mild/mild-moderate
- Patient prosthesis mismatch (PPM) insignificant*
- Mean gradient < 20 mmHg
- Clinical Efficacy [ Time Frame: 1 year ]
Clinical efficacy (at 1 year and thereafter)
- Freedom from all-cause mortality
- Freedom from all stroke
- Freedom from hospitalization for procedure- or valve-related causes
- Freedom from KCCQ Overall Summary Score <45 or decline from baseline of >10 point (i.e. Unfavourable Outcome)
- Valve-related clinical efficacy [ Time Frame: Up to 5 years ]
Valve-related clinical efficacy
- Freedom from bioprosthetic Valve Failure (defined as: Valve-related mortality OR Aortic valve re-operation/re-intervention OR Stage 3 haemodynamic valve deterioration)
- Freedom from stroke or peripheral embolism (presumably valve-related, after ruling out other non-valve aetiologies)
- Freedom from VARC Type 2-4 bleeding secondary to or exacerbated by antiplatelet or anticoagulant agents, used specifically for valve-related concerns (e.g. clinically apparent leaflet thrombosis)
- New York Heart Association (NYHA) classification [ Time Frame: Up to 5 years ]Change in heart failure symptoms from baseline as assessed by the New York Heart Association (NYHA) classification (at 30 days, 3 months, 6 months, 1 year and every year thereafter up to 5 years post-implantation)
- Change in quality of life as assessed by the Kansas City Cardiomyopathy [ Time Frame: 1 year ]Scale from 0 to 100 and summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent
- Change in exercise capacity measured as the 6-minute walk distance (6-MWD) [ Time Frame: 1 year ]Change in exercise capacity from baseline measured as the 6-minute walk distance (6-MWD) (at 30 days, 3 months, 6 months and 1 year post-implantation)
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 65 Years and older (Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- Male and Female
- Age ≥ 65 years at time of consent
- Women of non-childbearing potential
-
Severe degenerative calcific native aortic valve stenosis with the following criteria assessed either by resting or dobutamine stress TTE:
- Aortic valve area (AVA) < 1.0 cm2 or AVA index ≤ 0.6 cm2/m2 and
- Jet velocity > 4.0 m/s or mean gradient > 40 mmHg
-
Symptomatic aortic stenosis (AS), defined as a history of at least one of the following:
- Dyspnea that qualifies at NYHA class II or greater
- Angina pectoris
- Cardiac syncope
-
Subject is considered at intermediate or high risk for surgical valve replacement based on at least one of the following:
- EuroSCORE II ≥ 4%
- Agreement by the Heart Team that subject is at high operative risk of serious morbidity or mortality with surgical valve replacement
- The local Heart Team, including at least 1 cardiothoracic surgeon and 1 interventional cardiologist, deems the patient to be eligible for transfemoral TAVI.
- Perimeter-based aortic annulus diameter between ≥ 18 and ≤ 29 mm measured by computed tomography (CT) performed within 90 days prior to planned implantation
- Adequate iliofemoral access with minimum average vessel diameter of ≥ 6.0mm and acceptable level of vessel calcification and tortuosity for safe placement of the introducer sheath
- The distance from coronary ostia to aortic anulus > 12 mm
- Patient (or legal representative) understands the study requirements and the treatment procedures and provides written informed consent.
- The patient and the treating physician agree that the patient will return for all required post-procedure follow-up visits.
Exclusion Criteria:
Cardiovascular System:
- Patient has a congenital unicuspid or bicuspid aortic valve or non-calcified valves.
- Evidence of an acute myocardial infarction (MI) ≤ 30 days before the IMD implantation (defined as Q-wave MI or non-Q-wave MI with total CK elevation ≥ twice normal in the presence of CK-MB elevation and/or troponin elevation).
- Patient has had a cerebrovascular stroke or TIA within the past 90 days before IMD implantation.
- Patient has a hypertrophic obstructive cardiomyopathy.
- History of any therapeutic invasive cardiac procedure (including balloon aortic valvuloplasty) within 30 days prior to the planned IMD implantation (except for pacemaker implantation which is allowed).
- Distance between the aortic ascending and descending is less than 60 mm.
- Untreated clinically significant coronary artery disease requiring revascularization at the screening visit.
- Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20% by echocardiography, contrast ventriculography, or radionuclide ventriculography within 90 days prior.
- Patient with cardiogenic shock manifested by low cardiac output and hemodynamic instability and vasopressor dependence, or mechanical hemodynamic support
- Patients with clinically significant conduction abnormalities (clinically significant sinus bradycardia, sinus block or pauses, clinically significant atrioventricular (AV)-block >I) at screening and at time of valve implantation.
-
Patient has severe peripheral vascular disease:
- including aortic aneurysm defined as maximal luminal diameter > 5 cm or with documented presence of thrombus, marked tortuosity, narrowing of the abdominal aorta, severe unfolding of the thoracic aorta or thick [> 5 mm], protruding or ulcerated atheroma in the aortic arch) or
- symptomatic carotid or vertebral disease or successful treatment of carotid stenosis within 30 days before IMD implantation.
- Patient with iliofemoral vessel characteristics that would preclude safe passage of the introducer [severe calcification, tortuosity (> two 90-degree bends), diameter < 6mm, or subject has had an aorto-femoral bypass]
- Patient with active bacterial endocarditis within 6 months of planned IMD
- Patient has (echocardiographic/ CT and/or MRI) evidence of intra-cardiac mass, thrombus or vegetation.
- Patient has a pre-existing prosthetic heart valve in any position (Note: mitral ring is not an exclusion).
- Patient has severe mitral regurgitation, severe aortic regurgitation or severe tricuspid regurgitation, moderate or severe mitral stenosis (Baumgartner et al. 2017).
-
Patient has a need for emergency surgery for any reason at time of screening and valve implantation.
General:
- Any condition considered a contraindication for placement of a bioprosthetic valve (e.g. patient with contraindication to oral antiplatelet therapy)
- Patient with renal insufficiency (eGFR < 30 ml/min per the Cockcroft-Gault formula) and/ or renal replacement therapy and/ or has serum creatinine level > 3.0 mg/dL or 265 µmol/L replacement therapy at the time of screening
- Patient with significant pulmonary disease (FEV1 < 30%) or currently on home oxygen
- Severe pulmonary hypertension (e.g., pulmonary systolic pressure greater than two- thirds of systemic pressure )
- Patients with evidence of an active systemic infection or sepsis.
- Patient has a known hypersensitivity or contraindication to contrast media, bovine tissue, nitinol (titanium or nickel), contraindication to oral antiplatelet therapy (aspirin, ticlopidine or clopidogrel) or heparin.
- Patient has a haemoglobin < 9 g/dL, platelet count < 50,000 cells/mm3 or > 700.000 cells/mm3, or white blood cell count < 1.000 cells/mm3, history of bleeding diathesis or coagulopathy
- Patient has peptic ulcer disease or history of gastrointestinal bleeding within the past 3 months.
- Patient refuses blood transfusions.
- Patient has a life expectancy of less than 12 months due to non-cardiac, co-morbid conditions based on the assessment of the investigator at the time of enrolment.
- Patient is pregnant or breast feeding.
- Severe dementia (resulting in either inability to provide informed consent for the study/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).
- Other medical, social, or psychological conditions that in the opinion of the Investigator precludes the patient from appropriate consent or adherence to the protocol required follow-up exams.
- Patient is currently participating in another investigational drug or device study that has not reached its primary endpoint (excluding observational studies).
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04861805
Contacts
| Contact: Katharina Kiss, Dr | +4369913289414 | kkiss@productsandfeatures.com | |
| Contact: Monica Tocchi, MD, PhD | 9176841700 | m.tocchi@meditrial.net |
Locations
Show 23 study locations
Sponsors and Collaborators
P+F Products + Features GmbH
Meditrial USA Inc.
Investigators
| Principal Investigator: | Rimantas Benetis, Prof Dr | Lithuanian University of Health Sciences | |
| Principal Investigator: | Ignacio J Amato Santos, Dr | Hospital Clínico Universitario de Valladolid |
Additional Information:
| Responsible Party: | P+F Products + Features GmbH |
| ClinicalTrials.gov Identifier: | NCT04861805 |
| Other Study ID Numbers: |
CTP-VIE-001 |
| First Posted: | April 27, 2021 Key Record Dates |
| Last Update Posted: | November 1, 2023 |
| Last Verified: | October 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
Keywords provided by P+F Products + Features GmbH:
|
heart disease aortic valve SSAS symptomatic severe aortic stenosis heart valve |
Additional relevant MeSH terms:
|
Aortic Valve Stenosis Aortic Valve Disease Heart Valve Diseases |
Heart Diseases Cardiovascular Diseases Ventricular Outflow Obstruction |